组方藏药治疗肝囊型包虫病的临床疗效观察  

Observation of clinical curative effect of prescription Tibetan medicine in the treatment of hepatic cystic echinococcosis

作　　者：顿珠旦达 旦增曲珍 白玛 米玛卓嘎 贡桑曲珍[2] DUNZHU Danda;DANZENG Quzhen;BAI Ma;MIMA Zhuoga;GONGSANG Quzhen(Department of Hepatology,Tibetan Hospital of TAR,Lhasa,850000,China;Tibet Center for Disease Control and Prevention)

机构地区：[1]西藏自治区藏医院肝病科,拉萨850000 [2]西藏自治区疾病预防控制中心

出　　处：《中国中西医结合消化杂志》2022年第10期695-700,共6页Chinese Journal of Integrated Traditional and Western Medicine on Digestion

基　　金：国家卫生健康委包虫病防治研究重点实验室2020年开放课题项目(No:2020WZK2011)。

摘　　要：目的:评价组方藏药治疗肝囊型包虫病的临床疗效及安全性。方法:选择2019年8月—2020年8月收治的西藏那曲索县、巴青县确诊的94例肝囊型包虫病患者为研究对象。通过简单随机抽样方法,纳入口服组方藏药组(52例,观察组)和口服阿苯达唑组(42例,对照组)进行治疗。6个月后,依据藏医证候积分表评价患者的临床症状改善情况;通过B超检查观察两组患者治疗前后的病灶变化,评价临床疗效;检测治疗前后肝肾功能、血常规改变情况,对其安全性进行评价。结果:治疗后,观察组总有效率为94.23%(49/52),对照组为80.95%(34/42),差异无统计学意义(P>0.05);根据藏医证候积分观察临床症状,观察组治疗后临床症状均有改善,与对照组比较差异有统计学意义(P<0.05),对照组治疗后仅腹胀、乏力有改善,差异有统计学意义(P<0.05);B超检查显示治疗后两组的病灶均缩小,观察组缩小更为明显,但差异无统计学意义(P>0.05);安全性评价:治疗后,观察组患者的白细胞、ALT、AST指标低于对照组,差异有统计学意义(P<0.05)。结论:藏药秘诀清凉散、嘎布竹觉、十三味红花丸、驱虫卡擦散组方治疗肝囊型包虫病具有一定的临床疗效,安全性好,具有临床推广价值。Objective:To evaluate the clinical efficacy and safety of Tibetan medicine in the treatment of cystic echinococcosis.Methods:Ninety-four patients with hepatic cystic echinococcosis were diagnosed in Suo and Baqing County,Tibet Autonomous Region,during August 2019 to August 2020.According to the different treatment methods,the study group was divided into Tibetan medicine group(52 cases,the observation group)and Western medicine group(42 cases,the control group).After 6 months of treatment,the clinical efficacy of the two groups was observed and the clinical symptom improvement was evaluated according to the Tibetan medical syndrome score;the morphology of the masses before and after treatment was observed by ultrasound;the liver and kidney function and blood routine changes before and after treatment were observed to evaluate their safety.Results:After treatment,the total effective rate of the observation group was 94.23%(49/52),and the control group was 80.95%(34/42),and the difference was not statistically significant(P>0.05);the clinical symptoms were observed from the Tibetan medical syndrome integral,the clinical symptoms were improved after treatment in the observation group,and the difference was statistically significant(P<0.05),and the difference was statistically significant after treatment in the control group(P<0.05);ultrasound examination shown the abdominal mass became smaller in both group,and the shrinkage in the observation group was even more obvious,whereas,the difference was not statistically significant(P>0.05),and after treatment in terms of safety,the values of leukocytes,ALT,AST in the observation group were lower than those in the control group,and the difference was significant(P<0.05).Conclusion:The Tibetan medicine formula has certain clinical efficacy in the treatment of hepatic cystic echinococcosis,with safety grantee and clinical promotion value.

关 键 词：组方藏药 肝囊型包虫病 疗效分析 

分 类 号：R532.32[医药卫生—内科学]